Prelude Therapeutics
Song Mei has an extensive background in scientific research and holds multiple degrees in Biotechnology, Pharmacy, and Organic Chemistry. They have worked in various research positions at Incyte for over a decade before joining Prelude Therapeutics as a Principal Scientist in March 2021.
Prelude Therapeutics
3 followers
Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways.